CANC Performance — Tema Oncology ETF
Data updated: 2026-07-29
CANC returned +9.82% year to date and +60.01% over one year to May 2026. Over one year the fund beat its Health Care Equity category average: $100 grew to $160, against $129 for the category. Volatility over the past 12 months was 17.21% a year. In the 12 months to May 2026 the fund took in a net $65.2M, and assets reached $176.14M.
CANC Growth of $100
What $100 invested in Tema Oncology ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | CANC | Category average |
|---|---|---|
| 1 year (Jun 2025 – May 2026) | $160 | $129 |
| Since data start (Aug 2023 – May 2026) | $157 | $126 |
CANC Trailing Returns
Total returns to May 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +9.82% |
| 1 year | +60.01% |
| 3 years (annualised) | +17.16% |
CANC Annual Returns
Calendar-year total returns of Tema Oncology ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–May) | +9.82% |
| 2025 | +42.76% |
| 2024 | −5.35% |
| 2023 (Aug–Dec) | +5.53% |
CANC Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.9% | +5.8% | −3.0% | +2.5% | +1.5% | — | — | — | — | — | — | — |
| 2025 | +5.5% | 0.0% | −6.2% | +4.1% | −4.9% | +3.8% | +4.8% | +2.7% | +7.7% | +7.9% | +15.5% | −2.8% |
| 2024 | −0.9% | +8.0% | −0.5% | −5.3% | +0.4% | +1.0% | +9.0% | +1.6% | −5.0% | −2.6% | +0.6% | −10.2% |
| 2023 | — | — | — | — | — | — | — | −0.3% | −7.5% | −5.8% | +9.7% | +10.7% |
CANC Risk
Risk measures from monthly returns over Jun 2025 – May 2026.
- 1-year volatility (annualised): 17.21%
- Best month: +15.51% (Nov 2025)
- Worst month: −3.00% (Mar 2026)
CANC Fund Flows
Monthly money in and out of Tema Oncology ETF, from SEC Form N-PORT.
- 12-month net flow: $65.2M
- 12-month gross sales (incl. reinvestments): $74.9M
- Sales ÷ redemptions: 7.75×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| May 2026 | $0 | $2.3M | −$2.3M |
| Apr 2026 | $3.5M | $0 | $3.5M |
| Mar 2026 | $13.1M | $0 | $13.1M |
| Feb 2026 | $9.0M | $0 | $9.0M |
| Jan 2026 | $23.5M | $0 | $23.5M |
| Dec 2025 | $13.6M | $0 | $13.6M |
| Nov 2025 | $4.5M | $0 | $4.5M |
| Oct 2025 | $615K | $0 | $615K |
| Sep 2025 | $3.8M | $0 | $3.8M |
| Aug 2025 | $533K | $0 | $533K |
| Jul 2025 | $525K | $7.4M | −$6.9M |
| Jun 2025 | $2.2M | $0 | $2.2M |
CANC Assets Under Management
Net assets of Tema Oncology ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-05-31 | $176.14M |
| 2026-02-28 | $159.88M |
| 2025-11-30 | $104.84M |
| 2025-08-31 | $70.42M |
| 2025-05-31 | $66.84M |
| 2025-02-28 | $67.59M |
| 2024-11-30 | $48.89M |
| 2024-08-31 | $51.28M |
| 2024-05-31 | $22.39M |
| 2024-02-29 | $18.88M |
| 2023-11-30 | $15.81M |
| 2023-08-31 | $2.25M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.